Key features and details
- Mouse monoclonal [8C1-F10] to CRISPR-Cas9
- Suitable for: WB, ICC/IF
- Reacts with: Streptococcus pyogenes
- Isotype: IgG2b
Product nameAnti-CRISPR-Cas9 antibody [8C1-F10]
See all CRISPR-Cas9 primary antibodies
DescriptionMouse monoclonal [8C1-F10] to CRISPR-Cas9
Tested applicationsSuitable for: WB, ICC/IFmore details
Species reactivityReacts with: Streptococcus pyogenes
Recombinant fragment corresponding to Streptococcus pyogenes CRISPR-Cas9 (N terminal).
- ICC-IF: NIH-3T3 Cas9-expressing cells
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Store at -20°C.
Storage bufferPreservative: 0.02% Sodium azide
Concentration information loading...
PurityProtein G purified
Our Abpromise guarantee covers the use of ab210571 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||Use a concentration of 1 - 5 µg/ml. Detects a band of approximately 160 kDa (predicted molecular weight: 160 kDa).|
|ICC/IF||Use a concentration of 5 - 10 µg/ml.|
Relevance[FUNCTION] CRISPR (clustered regularly interspaced short palindromic repeat) is an adaptive immune system that provides protection against mobile genetic elements (viruses, transposable elements and conjugative plasmids). CRISPR clusters contain spacers, sequences complementary to antecedent mobile elements, and target invading nucleic acids. CRISPR clusters are transcribed and processed into CRISPR RNA (crRNA) (Probable). In type II CRISPR systems correct processing of pre-crRNA requires a trans-encoded small RNA (tracrRNA), endogenous ribonuclease 3 (rnc) and this protein. The tracrRNA serves as a guide for ribonuclease 3-aided processing of pre-crRNA. Subsequently Cas9/crRNA/tracrRNA endonucleolytically cleaves linear or circular dsDNA target complementary to the spacer. The target strand not complementary to crRNA is first cut endonucleolytically, then trimmed by 3'-5' exonucleolytically. DNA-binding requires protein and both RNA species. Cas9 probably recognizes a short motif in the CRISPR repeat sequences (the PAM or protospacer adjacent motif) to help distinguish self versus nonself.
- Cas9 antibody
- CRISPR-associated endonuclease Cas9/Csn1 antibody
- CRISPR-Cas9/Csn1 antibody
ab210571 stained in NIH3T3 cells. Untreated and Cas9 transfected cells were fixed with 4% paraformaldehyde (10min) at room temperature and incubated with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% triton for 1h at room temperature to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody ab210571 at 10µg/ml and ab6046 (Rabbit polyclonal to beta tubulin) at 1ug/ml overnight at +4°C. The secondary antibodies were ab150177 (colored green) used at 1 ug/ml and ab150087 (pseudo-colored red) used at 2ug/ml for 1hour at room temperature. DAPI was used to stain the cell nuclei (colored blue) at a concentration of 1.43µM for 1hour at room temperature.
All lanes : Anti-CRISPR-Cas9 antibody [8C1-F10] (Ab210571) at 1 µg/ml
Lane 1 : NIH3T3 non-transfected cell lysate
Lane 2 : NIH3T3 cells overexpressing CRISPR-Cas9
Lysates/proteins at 10 µg per lane.
All lanes : Goat polyclonal to Mouse IgG - H&L - Pre-Adsorbed (HRP) at 1/5000 dilution
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 160 kDa
Exposure time: 10 seconds
ab210571 has been referenced in 1 publication.
- Dastidar S et al. Efficient CRISPR/Cas9-mediated editing of trinucleotide repeat expansion in myotonic dystrophy patient-derived iPS and myogenic cells. Nucleic Acids Res 46:8275-8298 (2018). PubMed: 29947794